Terns Pharmaceuticals, Inc. (TERN)

Terns Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	1	-
Gross Profit	-	-	-	1	-
Selling, General & Admin	31.76	39.06	22.41	19.55	9
Research & Development	70.11	63.5	39.62	31.31	28.03
Operating Expenses	101.87	102.56	62.03	50.86	37.03
Operating Income	-101.87	-102.56	-62.03	-49.86	-37.03
Interest & Investment Income	13.29	12.9	2.11	0.17	0.06
Other Non Operating Income (Expenses)	-0.01	-0.31	-0.07	0.04	0.1
EBT Excluding Unusual Items	-88.59	-89.97	-59.99	-49.65	-36.87
Other Unusual Items	-	-	-	-	7.81
Pretax Income	-88.59	-89.97	-59.99	-49.65	-29.06
Income Tax Expense	0.26	0.24	0.36	0.51	0.81
Earnings From Continuing Operations	-88.85	-90.21	-60.35	-50.16	-29.87
Minority Interest in Earnings	-	-	-	-	0.52
Net Income	-88.85	-90.21	-60.35	-50.16	-29.35
Net Income to Common	-88.85	-90.21	-60.35	-50.16	-29.35
Shares Outstanding (Basic)	80	71	36	23	0
Shares Outstanding (Diluted)	80	71	36	23	0
Shares Change (YoY)	11.58%	97.76%	58.69%	7862.47%	55.60%
EPS (Basic)	-1.12	-1.27	-1.67	-2.21	-102.93
EPS (Diluted)	-1.12	-1.27	-1.67	-2.21	-102.93
Free Cash Flow	-70.06	-67.44	-49.38	-42.17	-30.39
Free Cash Flow Per Share	-0.88	-0.95	-1.37	-1.86	-106.58
Gross Margin	-	-	-	100.00%	-
Operating Margin	-	-	-	-4986.00%	-
Profit Margin	-	-	-	-5015.80%	-
Free Cash Flow Margin	-	-	-	-4216.70%	-
EBITDA	-101.55	-102.27	-61.55	-49.35	-36.63
D&A For EBITDA	0.32	0.29	0.48	0.51	0.39
EBIT	-101.87	-102.56	-62.03	-49.86	-37.03

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q